Partner Jeff Fessler Joins Client ContraVir Pharmaceuticals, Inc. at NASDAQ Opening Bell Ringing
Press Release – New York, NY – March 22, 2016 – Sichenzia Ross Friedman Ference LLP partner Jeff Fessler joined representatives of client ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, at the NASDAQ MarketSite in Times Square to ring the March 21 closing bell.
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. The company’s common stock has traded on The Nasdaq Capital Market under the symbol “CTRV” since February 27, 2015.
- Sichenzia Ross Ference Carmel LLP Represents New Era Helium in De-SPAC Transaction and Nasdaq Listing - December 9, 2024
- Sichenzia Ross Ference Carmel LLP represents Madison Global Partners, LLC in an Unsecured Senior Convertible Note and Warrant Offering up to $1 Million - December 6, 2024
- Sichenzia Ross Ference Carmel LLP Represents D. Boral Capital in $1.7 Million Registered Direct Offering of SRM Entertainment - December 5, 2024